At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6,735 enrolled
Drug / intervention
Aurora Xi New Nomogram Software 2.0 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Aurora Xi New Nomogram Software 2.0
In Brief
A clinical study evaluating Aurora Xi New Nomogram Software 2.0 and Aurora Xi Currently Approved Software 1.3 for Apheresis Related Hypotension. Completed, enrolled 6,735 participants across 3 sites.
Detailed Summary
A clinical trial to evaluate the safety and effectiveness of the Aurora Xi Plasmapheresis System with a new plasma collection volume nomogram.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsApheresis Related Hypotension
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedNov 2023
Enrollment StartNov 2023
Primary CompletionApr 2024
Study CompletionMay 2024
TodayJul 2026
First PostedNov 8, 2023
Enrollment StartNov 27, 2023
Primary CompletionApr 19, 2024
Study CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.6 years ago
Interventions
Aurora Xi New Nomogram Software 2.0device
Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
Aurora Xi Currently Approved Software 1.3device
Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System